Martin Shkreli
martin@martinshkreli.com
←
|
VRTX.xlsx
|
Main
Model
Trikafta
Orkambi
Symdeko
Kalydeco
CTX001
VX-880
VX-121
VX-548
inaxaplin
VX-634
IP
Compounds
A
B
C
1
Main
2
Brand
VX-121
3
Indication
Cystic Fibrosis
4
Clinical Trials
5
Phase III "SKYLINE 102"
6
VX-121/tezacaftor/VX-561 vs. Trikafta
7
8
Phase III "SKYLINE 103"
Martin Shkreli